(See the editorial commentary by Cranston on pages 635-8.)
The human papillomavirus (HPV) is the most prevalent viral sexually transmitted infection (STI) worldwide and is the cause of genital warts and HPV-associated neoplasia [1] . Men who have sex with men (MSM) are a major risk group for STIs including HIV and they have a high prevalence of anogenital HPV infection and HPVrelated lesions including anogenital warts, anal intraepithelial neoplasia, and anal cancer [2] [3] [4] . Data indicate that the incidence of anal cancer among MSM is high, with the highest rates among HIV-positive MSM [2, 5] . In a metaanalysis of published studies, overall, 63% of HIV-negative and 92% of HIV-positive MSM were infected with anal HPV. The overall prevalence of HPV 16, the HPV type most commonly associated with anal cancer, among HIV-negative and HIV-positive MSM was 12% and 35%, respectively [6] .
The quadrivalent HPV vaccine is effective in preventing infection with HPV types 6, 11, 16, and 18; in preventing the development of genital warts in males [7] ; and in protecting against anal intraepithelial neoplasia in MSM [8] . Mathematical modeling suggests that HPV vaccination of MSM is likely to be cost effective [9] . Studies have shown a high incidence of low-and high-risk genital HPV infection associated with new sexual partners among teenage females [10] . Such studies have underscored the need for HPV vaccination prior to the onset of sexual activity. No previous studies have been designed to examine factors associated with HPV infection among teenage MSM when initial infection with HPV would be expected to occur [11] . Such data would help to inform the development of policies that govern HPV vaccination of MSM. In this study, we sought to elucidate the determinants of initial anogenital HPV infection among teenage MSM and the proportion infected with HPV.
METHODS

Subjects and Recruitment
To be eligible for the Human Papillomavirus in Young People Epidemiological Research (HYPER) Study, participants had to be males aged 16 to 20 years who self-identified as being samesex attracted. Men were not required to have engaged in sex with other males.
Men were recruited between October 2010 and September 2012 via a number of avenues that focus on gay teenage males. These included community organizations that support gay teenagers with study promotion at social events such as dance parties; gay clubs at 6 Melbourne universities; gay community events including the Midsumma Festival; gay media including radio and magazine; the study Web site; and social networking Web sites including Facebook, Twitter, and Grindr. Recruitment also took place through 3 sexual health services in Melbourne.
The study nurse assessed men at a baseline visit and then 3, 6, and 12 months later. On each occasion, specimens were obtained for HPV DNA testing, blood was obtained for HPV serology, and men completed a questionnaire regarding their sexual experiences. Men were also examined for the presence of anogenital warts. The results from the baseline visit are presented here. Men were offered vaccination with Gardasil (Merck, NJ) free of charge after completing the 12-month visit.
Specimen Collection
Specimens were obtained from men for HPV DNA testing in the following order: an oral rinse, an anal canal swab, a perianal swab, and a penile swab. The oral rinse and penile swab were self-collected by men after watching a video that demonstrated how to self-collect these specimens [12] . The study nurse collected the anal and perianal swabs using a technique that prevents cross-contamination of HPV DNA between the 2 sites.
For the oral rinse men, rinsed and gargled 10 mL of saline for 20 seconds. The anal swab was obtained using a salinemoistened, flocked swab (Copan Flock Technologies) that was inserted 3 cm into the anal canal and rotated 6 times. The nurse then used a single-use paper emery board to gently exfoliate the epidermis of the perianal area within 5 cm of the anus. A saline-moistened swab was then rolled over the abraded area.
Men used a single-use paper emery board to gently exfoliate the epidermis over the entire penile shaft and glans penis and, if uncircumcised, the inner and outer aspects of the foreskin. Men then rolled a saline-moistened swab firmly over these areas. Swabs were placed in RNA (Ambion). A physician verified anal or penile warts.
Blood for HPV serology was collected in 10-mL serum collection tubes (Greiner Bio One International AG) and centrifuged at 4800 × g for 10 minutes to separate cells from serum. Serum samples were aliquoted and stored at −80°C until testing.
Laboratory Methods
HPV DNA Detection and Genotyping
Swab and oral rinse samples were tested at the regional HPV Labnet Reference Laboratory, Molecular Microbiology Department, Royal Women's Hospital, Melbourne. Cellular material from oral rinses was pelleted by centrifugation at 5000 × g for 15 minutes and resuspended in 400 µL of phosphate buffered saline. Total DNA was extracted from 200 μL of each swab and oral rinse sample on 1 of 2 automated extraction platforms with equal performance and using magnetic bead capture of nucleic acids, either the VERSANT kPCR Molecular System SP (Siemens) or the MagNA Pure 96 using the MagNA Pure 96 DNA and Viral NA small volume kit (Roche Diagnostics GmbH). Extracted DNA was prescreened to assess its integrity by quantitative polymerase chain reaction (PCR) amplification of a 260 base-pair product of the human beta-globin gene [13] . Samples were subsequently amplified for the HPV L1 gene using consensus primers PGMY09-PGMY11 [14] , and amplicons were detected using PCR enzyme-linked immunosorbent assay (ELISA; Roche Diagnostics GmbH) as described previously [15] . Briefly, a generic probe for detection of the presence of any HPV sequences in the sample was employed using biotin-labeled probes able to detect all mucosal HPV types [13, 15] . Samples that were positive by ELISA were further genotyped by HPV linear array genotyping assay (Roche Molecular Systems), which involved PCR amplification of target DNA followed by nucleic acid hybridization and detection of 37 HPV genotypes (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51-56, 58, 59 , 61, 62, 64, 66-73, 81-84, 82v, and 89). DNA samples that were negative for both beta-globin and HPV were considered unassessable and excluded from the analysis.
HPV Serology Serum samples were tested at PPD Vaccines and Biologics Lab. Antibodies against HPV types 6, 11, 16, and 18 were measured using a Luminex competitive immunoassay as previously described [16] .
STI Testing
Men were screened for pharyngeal and rectal Neisseria gonorrhoeae using modified Thayer-Martin media. First-void urine and a rectal swab were tested for Chlamydia trachomatis by strand displacement assay (Becton Dickinson ProbeTec ET). In addition, men were screened for syphilis using enzyme immunoassay (EIA) and rapid plasma reagin and tested for HIV using EIA.
The Alfred Hospital Research Ethics Committee ( project number 174/10) and the University of Melbourne Ethics Committee ( project ID 1034462) approved this study. Written informed consent was obtained from each participant. HYPER is registered on the Australia New Zealand Clinical Trials Registry (ACTRN12611000857909) and by the National Institutes of Health (NCT01422356). Participants gave informed consent for data sharing.
Statistical Analyses
A sample size of 200 men was required to provide acceptable 95% confidence intervals (CIs) around the expected proportion of men with HPV. Proportions were used for categorical variables. Median and interquartile ranges were used for continuous variables. CIs for proportions were calculated using exact methods. Univariate and multivariate logistic regression models were used to calculate odds ratios to estimate the association between potential risk factors and HPV infection. The χ 2 test with a P statistic was used to assess the significance of trends in HPV prevalence with number of lifetime sexual partners and with time since first sex. Concordance between HPV 6, 11, 16, and 18 DNA and antibody results were measured using kappa scores with 95% CIs. Statistical analyses were conducted using SPSS 19.0.
RESULTS
Participant Characteristics
Two hundred males aged 16 to 20 years were recruited into the study. The characteristics of men including circumcision status Men reported a median duration of 1.9 years since first receptive anal sex with a man. Thirty-six percent of men were recruited from gay community sources, universities, or by word of mouth and 64% were recruited from sexual health clinics.
Anal warts were present in 7.0% of men and penile warts were present in 1.0% of men. The proportion with pharyngeal gonorrhea, rectal gonorrhea, urethral chlamydia, rectal chlamydia, and early latent syphilis at baseline was 3.0%, 5.5%, 3.0%, 4.0%, and 1.0%, respectively. All men were HIV negative.
HPV DNA Detection and Genotypes
One anal swab sample and 1 perianal sample that was unavailable as well as 3 perianal samples and 1 penile swab sample that were beta-globin negative were excluded from the analysis. The proportion of men with each of the 37 HPV types detected by PCR is shown in Table 2A by anatomical site. Overall, 39.0% (95% CI, 32.2%-46.1%) of men had at least 1 of the 37 HPV types detected at any of the anatomical sites tested, with 23.0% (95% CI, 17.4%-29.5%) having at least 1 of the quadrivalent vaccine-preventable types (HPV 6, 11, 16, and 18) present. The prevalence of HPV of any type was significantly higher in the anal canal (30.8%; 95% CI, 24.5%-37.7%) than the penis (9.5%; 95% CI, 5.8%-14.5%; P < .001) and oral rinse (2.0%; 95% CI, .6%-5.1%; P < .001). The proportion of men who had at least 1 of the quadrivalent vaccine-preventable HPV types was higher in the anal canal (19.7%; 95% CI, 14.4%-25.9%) than the penis (4.5%; 95% CI, 2.1%-8.4%; P < .001) and oral rinse (0.5%; 95% CI, 0%-2.8%; P < .001). There was high concordance between HPV types detected from the anal canal and perianal swabs (kappa = 0.80; 95% CI, .71-.89).
At least 1 high-risk HPV type was found at any site in 31.0% (95% CI, 24.7%-38.0%) of men. Anal HPV type 16 DNA was found in 5.1% (95% CI, 2.4%-9.1%) of men. Multiple HPV DNA types were commonly found on the penis and in the anal canal. Infection with ≥2 HPV types was present in 11.0% of men (Table 2B) . Anal HPV was absent in 27 of the 30 men who reported no prior receptive anal sex.
HPV Seropositivity
The proportion of men who were seropositive for HPV types 6, 11, 16, and 18 was 12.5% (95% CI, 8.3%-17.9%), 7.0% (95% CI, 3.9%-11.5%), 3.5% (95% CI, 1.4%-7.1%), and 3.0% (95% CI, 1.1%-6.4%), respectively. Five percent (95% CI, 2.4%-9.0%) were seropositive for 2 or more HPV types. Concordance between HPV DNA and antibody results ranged from low to moderate (kappa scores, 0.14-0.50) between the 4 HPV types (Table 3) .
Factors Associated With Anal and Penile HPV DNA Detection
The factors associated with detection of HPV DNA of any type in the anal canal and penis are shown in Table 4A Figure 1A , C, E, and G. The proportion of men with anal HPV DNA of any type increased significantly from 10.0% in men who reported no prior receptive anal sex to 47.3% in men who reported 4 or more receptive anal sex partners (P < .001). Similarly, the proportion of men with anal HPV DNA of any type increased significantly, with increasing numbers of receptive anal sex partners with whom condoms were used inconsistently, with HPV among 52.0% among men who had 2 or more such partners (P = .002). The proportion of men with HPV type 16 DNA increased significantly from 0% in men who reported no prior receptive anal sex to 7.9% in men who reported 4 or more receptive anal sex partners (P = .044). Among the 30 men who had never had receptive anal sex, 70% reported being fingered anally and 83% reported receiving penile contact with their anus without penetration. The proportion of men with penile HPV DNA of any type increased significantly from 3.7% in men who reported no prior insertive anal sex to 14.8% in men who reported 4 or more insertive anal sex partners (P = .014). The proportion of men with penile HPV DNA of any type increased significantly from 6.2% in men who reported no prior vaginal sex to 57.1% in men who reported 4 or more vaginal sex partners (P < .001).
Trends in the proportion of men with anal and penile HPV DNA and time since first anal or vaginal sex are shown in Figure 1B , D, F, and H. The proportion of men with anal HPV DNA of any type, anal HPV 16 DNA specifically, and penile HPV DNA of any type increased significantly with time since first anal sex with another man. The proportion of men with penile HPV DNA of any type increased significantly with time since first vaginal sex with a woman.
When asked at the first study visit if they would be willing to disclose their sexuality to a doctor if the HPV vaccine was available free of charge, 85.5% indicated they would; 96.0% of men accepted HPV vaccination following completion of the study. Of the 173 men who had a doctor who provided care, 55.5% had already disclosed their sexuality for other reasons.
DISCUSSION
In this study, the proportion of men infected with HPV increased with each additional reported sex partner. These data suggest early and high per partner transmission of HPV among MSM soon after their first sexual experience. These data indicate that HPV vaccination needs to commence early for maximal prevention of HPV among MSM. While there have been previous studies of anal HPV among MSM, most of these cases have been in older men, most of whom have already had high numbers of sexual partners and who, in many cases, are HIV positive. These studies have shown that most adult MSM have anal HPV infection [6] . In contrast, data from this study suggest a greater prevalence of anal HPV among teenage MSM, from men with limited sexual experience to those who have accrued an increasing number of receptive anal sex partners. This applies to anal HPV 16 specifically, the HPV type most commonly found in anal cancers; HPV 16 increased in prevalence with increasing numbers of receptive anal sex partners. Approximately 10% of men who reported never receiving anal sex had anal HPV detected, possibly reflecting transmission via sexual behaviors other than receptive anal sex.
Our study is unique in that it is one of the first to specifically focus on initial HPV infection among teenage MSM, with men recruited from a variety of sources. Data on HPV infection in teenage MSM are scarce. In a systematic review, there were only 6 studies that combined provided data on anal HPV for a total of 698 MSM aged ≤25 years, most of whom were aged >20 years. Previous studies have had potential biases, for example, sole recruitment from clinics including STD clinics; selection criteria that are potentially biased toward higher-risk or lowerrisk men; and studies where teenage MSM only comprised a small subset of men [11] . Most data are from a study that was designed to determine HPV vaccine efficacy among MSM rather than HPV prevalence. In that study, MSM were aged 17 to 27 years, with a median age of 22 years, and reported fewer than 5 lifetime sexual partners [17] . In another study, the number of male receptive anal sex partners was also found to be significantly associated with anal infection, as in our study. However, the number of men in that study was much smaller than in our study and men were on average older and selected based on sexual behavior [18] . Among men in this study, the proportion with penile HPV also rose incrementally with increasing numbers of insertive anal sex partners but to an overall proportion that remained lower than for anal infection. Furthermore, among men who were also having sex with women, the prevalence of penile HPV rose with increasing number of vaginal sex partners. While there have been studies of early genital HPV acquisition in young females, which as in this study suggests a high rate of HPV transmission per partner [10] , ours is the first study to examine early acquisition of penile HPV in any teenage male population. Although several studies have shown that male circumcision is protective against penile HPV infection, these are the first data to suggest there is also a protective effect of male circumcision against HPV among MSM, indicating that circumcision may be protective against the acquisition of penile HPV infection via insertive anal sex [19] [20] [21] . While receptive oral sex among men in this study was common, oral HPV was uncommon.
The rapid rise in HPV prevalence seen in this population of young MSM underscores the need to vaccinate such men against HPV at the earliest possible time, ideally prior to the onset of sexual activity. The age of first anal sex among MSM in Australia has fallen over time. In one study, the median age of first anal sex among younger MSM was 18 [22] , similar to age 17 years reported in this study.
To date, while the number of countries with HPV vaccination programs targeting females increases, with evidence of falling HPV-related disease [23] [24] [25] [26] , no country, except for Australia, has implemented universal vaccination of schoolaged boys despite evidence for the potential additional benefit this might confer [27] . While universal vaccination of schoolaged boys would confer maximal prevention against HPV among MSM, in its absence, opportunistic vaccination of young MSM could still be beneficial. However, for targeted vaccination of MSM to achieve maximum HPV prevention, young MSM would need to be willing to disclose their sexuality in order to obtain the vaccine at a time when they are not already infected with HPV. The willingness to make such a disclosure may differ between different populations of MSM. In one study, MSM would only have disclosed their sexuality to obtain the HPV vaccine after a median of 15 male sex partners, a point at which many would already have been infected [28] .
There are limitations to this study. First, the findings from this study may or may not extend to other populations of teenage MSM. A lower HPV prevalence would be expected among teenaged MSM who are less sexually experienced than those in this study. In such populations the potential benefit from opportunistic HPV vaccination targeting young MSM would be greater. Second, the data on HPV presented here are cross-sectional, with detection of HPV at 1 time point. Studies suggest that detection of HPV DNA at a single time point may represent contamination from very recent sexual contact as opposed to established HPV infection, which has generally been defined by the presence of the same HPV type at 2 separate time points [29] .
In this study, the overall proportion of men with anal HPV was 3 times higher than for penile HPV. This may suggest that the anal mucosa is more susceptible to HPV infection than the keratinized, squamous epithelium of the penis or that the duration of anal HPV infection is longer, or it may reflect more receptive anal sex. Longitudinal studies have verified the persistence of HPV infection in the anus among MSM, particularly those who are HIV positive [30, 31] .
In Australia, starting in 2013, free universal HPV vaccination was rolled out among males aged 12 to 13 years with a catch-up program in 2013 and 2014 for males aged 14 to 15 years. This will be part of an existing national school-based vaccination program that targets girls aged 12 to 13 years. Of interest will be the effect that male vaccination has on the prevalence of HPV-associated disease in males including MSM, though the benefits from cancer prevention may not be evident for years. The additional benefit to men and women that the 9-valent HPV vaccine, which also protects against HPV types 31, 33, 45, 52, and 58, warrants research.
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